Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/MAPK Pathway

Overview

Journal Front Pharmacol

Date 2022 Apr 21

PMID 35444554

Authors

Hui Zheng

Nannan Xu

Zihao Zhang

Fen Wang

Jie Xiao

Xiaoping Ji

Affiliations

Soon will be listed here.

Abstract

Doxorubicin (DOX)-induced cardiotoxicity is a highly concerning issue, and the mechanism by which DOX induces cardiotoxicity is likely to be multifactorial. NADPH oxidase (NOX) is associated with DOX-induced cardiotoxicity. Setanaxib (GKT137831), a preferential direct inhibitor of NOX1 and NOX4, can delay or prevent the progression of many cardiovascular disorders by inhibiting reactive oxygen species (ROS) generation. In this study, we investigated the role of GKT137831 in ameliorating DOX-induced cardiotoxicity and the potential mechanisms of its action. The mice model of cardiotoxicity induced by DOX was established, and GKT137831 treatment was performed at the same time. Neonatal rat cardiomyocytes (NRCMs) were treated with DOX or GKT137831 for experiments. We found that DOX administration impaired cardiac function , reflected by decreased left ventricular ejection fraction (LVEF) and fractional shortening (FS%). DOX also impaired the viability of NRCMs . In addition, DOX increased the levels of NOX1 and NOX4 expression and ROS production and the cardiomyocyte apoptosis rate, both and . GKT137831 improved cardiac function, as indicated by the increased LVEF and FS%. GKT137831 improved NRCM viability. It also decreased ROS production and the cardiomyocyte apoptosis rate. Apoptotic indices, such as cleaved PARP (c-PARP), cleaved caspase 3 (CC3) and BAX expression levels, were decreased, and the antiapoptotic index of Bcl-2 expression was increased. DOX markedly activated phosphorylated JNK, ERK and p38 proteins in NRCMs. Specific inhibitors of JNK (SP600125), ERK (PD98059) or p38 (SB203580) inhibited DOX-induced apoptosis of NRCMs. GKT137831 pretreatment inhibited excessive DOX-induced MAPK pathway activation. This study revealed that GKT137831 can alleviate DOX-induced cardiomyocyte apoptosis by inhibiting NOX1/4-driven ROS production. The upregulation of MAPK pathway induced by NOX1/4-derived ROS production may be the potential mechanism of GKT137831 action. GKT137831 may be a potential drug candidate to ameliorate DOX-induced cardiotoxicity.

Citing Articles

Reduced glutathione enhances adipose tissue-derived mesenchymal stem cell engraftment efficiency for liver fibrosis by targeting TGFβ1/SMAD3/NOX4 pathway.

Yu S, Wang Y, Shi Y, Yu S, Zhao B, Liao N Bioeng Transl Med. 2025; 10(2):e10735.

PMID: 40060764 PMC: 11883125. DOI: 10.1002/btm2.10735.

Autophagy-mediated activation of the AIM2 inflammasome enhances M1 polarization of microglia and exacerbates retinal neovascularization.

Liu X, Zhou Q, Meng J, Zuo H, Li R, Zhang R MedComm (2020). 2024; 5(8):e668.

PMID: 39081514 PMC: 11286542. DOI: 10.1002/mco2.668.

Roles of reactive oxygen species in inflammation and cancer.

Yu Y, Liu S, Yang L, Song P, Liu Z, Liu X MedComm (2020). 2024; 5(4):e519.

PMID: 38576456 PMC: 10993368. DOI: 10.1002/mco2.519.

NADPH Oxidases and Oxidative Stress in the Pathogenesis of Atrial Fibrillation.

Ramos-Mondragon R, Lozhkin A, Vendrov A, Runge M, Isom L, Madamanchi N Antioxidants (Basel). 2023; 12(10).

PMID: 37891912 PMC: 10604902. DOI: 10.3390/antiox12101833.

Primary Biliary Cholangitis: Promising Emerging Innovative Therapies and Their Impact on GLOBE Scores.

Sohal A, Kowdley K Hepat Med. 2023; 15:63-77.

PMID: 37312929 PMC: 10259525. DOI: 10.2147/HMER.S361077.

References

Altenhofer S, Kleikers P, Radermacher K, Scheurer P, Hermans J, Schiffers P . The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci. 2012; 69(14):2327-43. PMC: 3383958. DOI: 10.1007/s00018-012-1010-9. View

Jha J, Thallas-Bonke V, Banal C, Gray S, Chow B, Ramm G . Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Diabetologia. 2015; 59(2):379-89. PMC: 6450410. DOI: 10.1007/s00125-015-3796-0. View

Manea S, Constantin A, Manda G, Sasson S, Manea A . Regulation of Nox enzymes expression in vascular pathophysiology: Focusing on transcription factors and epigenetic mechanisms. Redox Biol. 2015; 5:358-366. PMC: 4501559. DOI: 10.1016/j.redox.2015.06.012. View

Zeng C, Duan F, Hu J, Luo B, Huang B, Lou X . NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol. 2020; 34:101523. PMC: 7327979. DOI: 10.1016/j.redox.2020.101523. View

Sheehan A, Carrell S, Johnson B, Stanic B, Banfi B, Miller Jr F . Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis. 2011; 216(2):321-6. PMC: 3110523. DOI: 10.1016/j.atherosclerosis.2011.02.028. View

Berthiaume J, Wallace K . Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2006; 23(1):15-25. DOI: 10.1007/s10565-006-0140-y. View

McLaughlin D, Zhao Y, ONeill K, Edgar K, Dunne P, Kearney A . Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2. Br J Pharmacol. 2017; 174(21):3677-3695. PMC: 5647180. DOI: 10.1111/bph.13773. View

McGowan J, Chung R, Maulik A, Piotrowska I, Walker J, Yellon D . Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017; 31(1):63-75. PMC: 5346598. DOI: 10.1007/s10557-016-6711-0. View

Gage M, Thippeswamy T . Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases. CNS Drugs. 2021; 35(1):1-20. PMC: 7893831. DOI: 10.1007/s40263-020-00787-5. View

10.

Douglas G, Bendall J, Crabtree M, Tatham A, Carter E, Hale A . Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE⁻/⁻ mice. Cardiovasc Res. 2012; 94(1):20-9. PMC: 3307381. DOI: 10.1093/cvr/cvs026. View

11.

Sumimoto H . Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008; 275(13):3249-77. DOI: 10.1111/j.1742-4658.2008.06488.x. View

12.

Son Y, Cheong Y, Kim N, Chung H, Kang D, Pae H . Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?. J Signal Transduct. 2011; 2011:792639. PMC: 3100083. DOI: 10.1155/2011/792639. View

13.

Goormaghtigh E, Huart P, Brasseur R, Ruysschaert J . Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives. Biochim Biophys Acta. 1986; 861(1):83-94. DOI: 10.1016/0005-2736(86)90374-3. View

14.

Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu Y, Liu L . Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639-42. DOI: 10.1038/nm.2919. View

15.

Zhao Q, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X . NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways. Circulation. 2015; 131(7):643-55. PMC: 4568756. DOI: 10.1161/CIRCULATIONAHA.114.011079. View

16.

Zhao Y, McLaughlin D, Robinson E, Harvey A, Hookham M, Shah A . Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res. 2010; 70(22):9287-97. PMC: 2984551. DOI: 10.1158/0008-5472.CAN-10-2664. View

17.

Gorin Y, Cavaglieri R, Khazim K, Lee D, Bruno F, Thakur S . Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol. 2015; 308(11):F1276-87. PMC: 4451325. DOI: 10.1152/ajprenal.00396.2014. View

18.

Andrade Louzada R, Corre R, Ameziane El Hassani R, Meziani L, Jaillet M, Cazes A . NADPH oxidase DUOX1 sustains TGF-β1 signalling and promotes lung fibrosis. Eur Respir J. 2020; 57(1). DOI: 10.1183/13993003.01949-2019. View

19.

Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A . NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005; 112(24):3754-62. DOI: 10.1161/CIRCULATIONAHA.105.576850. View

20.

Zeng S, Yang L, Yan Q, Gao L, Lu H, Yan P . Nox1/4 dual inhibitor GKT137831 attenuates hypertensive cardiac remodelling associating with the inhibition of ADAM17-dependent proinflammatory cytokines-induced signalling pathways in the rats with abdominal artery constriction. Biomed Pharmacother. 2018; 109:1907-1914. DOI: 10.1016/j.biopha.2018.11.077. View